Transmucosal Drug Delivery Devices Market Report 2025

This Transmucosal Drug Delivery Devices market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The transmucosal drug delivery devices market size has grown strongly in recent years. It will grow from $50.24 billion in 2024 to $55.04 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to the need for rapid relief from angina, the effectiveness of sublingual delivery for quick absorption into the bloodstream, desire to bypass gastrointestinal degradation, development of buccal tablets, the need for non-invasive delivery of peptides and proteins.

The transmucosal drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $78.21 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to the development of smart drug delivery systems, increased prevalence of chronic diseases, growing focus on personalized medicine, aging population with higher medication needs, and increased awareness. Major trends in the forecast period include expansion in therapeutic applications, customizing drug delivery devices for personalized medicine, regulatory approvals and guidelines, emerging markets, eco-friendly devices, and innovative formulations.

The increasing prevalence of chronic diseases is expected to drive the growth of the transmucosal drug delivery devices market in the coming years. Chronic diseases are long-lasting conditions that typically develop gradually and persist over time, often requiring ongoing medical management to control symptoms and prevent complications. The rise in chronic diseases can be attributed to factors such as lifestyle choices, aging populations, environmental influences, challenges within healthcare systems, and urbanization. Transmucosal drug delivery devices are employed in managing chronic diseases by providing controlled and efficient medication delivery, ensuring sustained therapeutic levels to manage symptoms and enhance patient adherence. For example, in August 2023, a report from the Leukemia & Lymphoma Society (LLS), a US-based nonprofit organization, indicated that in the US, a person is diagnosed with leukemia, lymphoma, or myeloma approximately every three minutes. In 2023, an estimated 184,720 individuals were expected to be diagnosed, accounting for 9.4% of the projected 1,958,310 new cancer cases for the year. Therefore, the rising prevalence of chronic diseases is fueling the growth of the transmucosal drug delivery devices market.

Leading companies in the transmucosal drug delivery devices sector are actively pursuing innovative solutions such as proprietary transdermal patch delivery platforms, which are designed to improve drug absorption, enhance patient compliance, and offer convenience. These platforms utilize specialized technologies owned by companies to administer medications through the skin, ensuring controlled release and optimized therapeutic outcomes. For example, in January 2024, Starton Therapeutics Inc., a US-based biotechnology firm, introduced STARSILON, a novel proprietary transdermal patch delivery platform. This platform is specifically designed to deliver difficult-to-formulate active pharmaceutical ingredients (APIs) over an extended period, thereby expanding the options for transdermal drug delivery and enhancing therapeutic efficacy through sustained release mechanisms.

In April 2023, Difgen Pharmaceuticals, an India-based pharmaceutical company, acquired Aveva Drug Delivery Services for an undisclosed sum. This strategic acquisition is intended to bolster Difgen Pharmaceuticals' drug delivery capabilities and incorporate advanced technologies into its pharmaceutical product portfolio. Aveva Drug Delivery Services, based in the US, specializes in manufacturing transdermal delivery systems (TDS) and oral dissolvable films (ODF).

Major companies operating in the transmucosal drug delivery devices market are Johnson & Johnson, Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, Becton Dickinson and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Catalent Inc., AptarGroup, Glenmark Pharmaceuticals Limited, Stevanato Group S.p.A, Lifevision Healthcare Private Limited, Noven Pharmaceuticals, SAVA Healthcare Limited, Antares Pharma Inc., Kaizen Pharmaceuticals Pvt. Ltd., Lucky Pharma Pvt. Ltd., Maya Biotech Pvt. Ltd, AdvaCare Pharma LLP, Satsuma Pharmaceuticals Inc., Biophar Lifesciences Private Limited, Fibovil Pharmaceuticals Private Limited, Slan Medicinal Holdings Ltd.

North America was the largest region in the transmucosal drug delivery devices market in 2024. The regions covered in the transmucosal drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the transmucosal drug delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Transmucosal drug delivery devices are medical instruments designed to administer drugs through mucous membranes, such as those found in the mouth, nose, or rectum, allowing for rapid absorption into the bloodstream. These devices are particularly useful for delivering medications that are poorly absorbed by the gastrointestinal tract or require swift onset of action, such as pain relief or hormone therapy. Their primary function is to circumvent the digestive system, offering a direct and efficient route for drug delivery.

The two main categories of transmucosal drug delivery devices are passive transmucosal drug delivery and active transmucosal drug delivery. Passive transmucosal drug delivery involves the absorption of drugs through mucous membranes without external energy or active transport mechanisms. Various types of products include buccal tablets, oral sprays, sublingual films, wafers, gels, medicated confectionery, among others, used for treating conditions such as pain management, addiction, and hormonal therapies. End users include academic and research institutions, pharmaceutical and biotechnology firms, diagnostic laboratories, and hospitals.

The transmucosal drug delivery devices research report is one of a series of new reports that provides transmucosal drug delivery devices market statistics, including the transmucosal drug delivery devices industry's global market size, regional shares, competitors with a transmucosal drug delivery devices market share, detailed transmucosal drug delivery devices market segments, market trends, and opportunities, and any further data you may need to thrive in the transmucosal drug delivery devices industry. This transmucosal drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The transmucosal drug delivery devices market consists of sales of sublingual sprays, nasal drops, rectal suppositories, and sublingual tablets. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.